Live Analyst Rating Changes 1525 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Benjamin Jackson CFA
JEF
Benjamin Jackson CFA
Jefferies
Wall Street Analyst
★★★★☆
#587
on 13Foresight · ranked by our own returns
67%
Success Rate
+27.9%
Average Return
2 of 3 calls profitable · +12.8% vs benchmark
🔒 5-year track record is Pro. Showing 1-year — upgrade.
📈 Across the calls we could measure, roughly 67% of Benjamin Jackson CFA's ratings turned a profit when each position was held for 1 year — averaging +27.9% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

35 Buy 9 Hold 4 Sell
Benjamin's Stock Coverage 16 ratings · 2026-06-19
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
GB:0DPB
Bavarian Nordic AS
 May 19, 2026 BUY Strong Buy
+95.2% avg upside
5 analysts
$280.00
54.61% Upside
 ·
FR:IPN
Ipsen
 May 17, 2026 HOLD Buy
-21.4% avg upside
17 analysts
$117.00
25.93% Downside
 ·
CH:GALD
Galderma Group AG
 Apr 23, 2026 BUY Strong Buy
+5.3% avg upside
10 analysts
$190.00
8.67% Upside
 ·
ZLDPF
Zealand Pharma
 Apr 19, 2026 BUY Buy
+93.0% avg upside
11 analysts
$78.16
73.71% Upside
 ·
CH:COPN
COSMO Pharmaceuticals N.V.
 Mar 25, 2026 BUY Strong Buy
+114.1% avg upside
3 analysts
$140.00
106.19% Upside
 ·
GMAB
Genmab
 Feb 17, 2026 BUY Buy
+38.2% avg upside
26 analysts
$41.50
63.43% Upside
 -11.5%
GB:0MGB
Genmab A/S
 Feb 16, 2026 BUY Buy
+32.3% avg upside
22 analysts
$2650.00
64.16% Upside
 ·
CH:NOVN
Novartis AG
 Feb 04, 2026 HOLD Buy
-10.2% avg upside
30 analysts
$110.00
8.34% Downside
 ·
FR:SAN
Sanofi
 Dec 29, 2025 BUY Strong Buy
+33.0% avg upside
30 analysts
$100.00
36.02% Upside
 ·
CH:ROP
Roche Holding AG
 Oct 27, 2025 SELL Buy
+3.2% avg upside
23 analysts
$230.00
28.75% Downside
 ·
GB:0QIU
Novo Nordisk
 Oct 27, 2025 SELL Hold
+45.6% avg upside
28 analysts
$290.00
0.58% Upside
 ·
GB:GSK
GlaxoSmithKline
 Jul 30, 2025 HOLD Hold
-3.3% avg upside
25 analysts
$1450.00
26.05% Downside
 ·
GB:AZN
AstraZeneca
 Jul 29, 2025 HOLD Strong Buy
+11.9% avg upside
26 analysts
$10900.00
18.83% Downside
 ·
AKBLF
ALK-abello
 Jan 31, 2025 BUY Strong Buy
-29.5% avg upside
1 analyst
$28.63
29.54% Downside
 +77.8%
DE:EVT
Evotec
 Nov 13, 2024 HOLD Buy
+261.3% avg upside
8 analysts
$6.80
47.49% Upside
 ·
EVO
Evotec AG
 Oct 07, 2024 HOLD Strong Buy
+287.7% avg upside
9 analysts
$3.80
45.61% Upside
 +17.4%
🔒 11 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Benjamin Jackson CFA — Frequently Asked Questions
How accurate are Benjamin Jackson CFA's stock ratings?
Based on the calls 13Foresight could measure, about 67% of Benjamin's ratings were profitable over a one-year hold, with an average return of +27.9% per rating, or +12.8% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Benjamin ranked on 13Foresight?
Benjamin Jackson CFA is currently ranked #587 with a 4-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Benjamin cover?
Benjamin most recently has ratings on GB:0DPB, FR:IPN, CH:GALD, ZLDPF, CH:COPN, GMAB, GB:0MGB, CH:NOVN, FR:SAN, CH:ROP, GB:0QIU, GB:GSK and 4 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.